The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
812
Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Adverse Event Recording
Time frame: From Baseline to Week 53 (Visit 16)
Diastolic Blood Pressure (DBP).
Time frame: From Baseline to Week 52 (Visit 15)
Systolic Blood Pressure (SBP)
Time frame: From Baseline to Week 52 (Visit 15)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Forest Investigative Site 083
Birmingham, Alabama, United States
Forest Investigative Site 004
Foley, Alabama, United States
Forest Investigative Site 038
Gulf Shores, Alabama, United States
Forest Investigative Site 124
Muscle Shoals, Alabama, United States
Forest Investigative Site 023
Chandler, Arizona, United States
Forest Investigative Site 073
Goodyear, Arizona, United States
Forest Investigative Site 100
Green Valley, Arizona, United States
Forest Investigative Site 117
Mesa, Arizona, United States
Forest Investigative Site 065
Mesa, Arizona, United States
Forest Investigative Site 102
Phoenix, Arizona, United States
...and 125 more locations